Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly Income from Continuing Operations of 205991000.0 for Q1 2026, up 1228.66% year-on-year from 15503712.44 in Q1 2025, and up 84.67% on a QoQ basis from 111543000.0 in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of Income from Continuing Operations data on file, last reported at 205991000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 1228.66% year-over-year to 205991000.0; the trailing twelve-month figure through Mar 2026 stood at 543940000.0 (up 336.01% YoY), and the FY2025 full-year result was 313747000.0, up 212.79% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 205991000.0, up from 111543000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 292683000.0 in Q3 2025 and bottomed at 405920000.0 in Q3 2022.
- The 5-year median for Income from Continuing Operations is 83763000.0 (2024), against an average of 77874470.59.
- The widest annual swing landed in 2025, when Income from Continuing Operations sank 292.43%; it then soared 1228.66% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 207493000.0 in 2022, then jumped by 33.55% to 137870000.0 in 2023, then jumped by 39.24% to 83763000.0 in 2024, then surged by 233.17% to 111543000.0 in 2025, then surged by 84.67% to 205991000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 205991000.0 (Q1 2026), 111543000.0 (Q4 2025), and 292683000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 205.99 Mn |
| Dec 31, 2025 | 111.54 Mn |
| Sep 30, 2025 | 292.68 Mn |
| Jun 30, 2025 | -66.28 Mn |
| Mar 31, 2025 | -18.25 Mn |
| Dec 31, 2024 | -83.76 Mn |
| Sep 30, 2024 | -111.57 Mn |
| Jun 30, 2024 | -16.89 Mn |
| Mar 31, 2024 | -65.94 Mn |
| Dec 31, 2023 | -137.87 Mn |
| Sep 30, 2023 | 147.75 Mn |
| Jun 30, 2023 | -276.02 Mn |
| Mar 31, 2023 | -174.10 Mn |
| Dec 31, 2022 | -207.49 Mn |
| Sep 30, 2022 | -405.92 Mn |
| Jun 30, 2022 | -277.40 Mn |
| Mar 31, 2022 | -240.34 Mn |
| Dec 31, 2021 | -258.46 Mn |
| Sep 30, 2021 | -204.51 Mn |
| Jun 30, 2021 | -189.56 Mn |
| Mar 31, 2021 | -200.29 Mn |
| Dec 31, 2020 | -243.54 Mn |
| Sep 30, 2020 | -253.29 Mn |
| Jun 30, 2020 | -179.23 Mn |
| Mar 31, 2020 | -182.22 Mn |
| Dec 31, 2019 | -276.19 Mn |
| Sep 30, 2019 | -208.54 Mn |
| Jun 30, 2019 | -219.48 Mn |
| Mar 31, 2019 | -181.92 Mn |
| Dec 31, 2018 | -211.44 Mn |
| Sep 30, 2018 | -245.28 Mn |
| Jun 30, 2018 | -163.56 Mn |
| Mar 31, 2018 | -141.21 Mn |
| Dec 31, 2017 | -142.23 Mn |
| Sep 30, 2017 | -122.94 Mn |
| Jun 30, 2017 | -118.42 Mn |
| Mar 31, 2017 | -107.29 Mn |
| Dec 31, 2016 | -113.23 Mn |
| Sep 30, 2016 | -104.47 Mn |
| Jun 30, 2016 | -90.13 Mn |
| Mar 31, 2016 | -102.97 Mn |
| Dec 31, 2015 | -90.72 Mn |
| Sep 30, 2015 | -76.79 Mn |
| Jun 30, 2015 | -71.35 Mn |
| Mar 31, 2015 | -51.21 Mn |
| Dec 31, 2014 | -43.48 Mn |
| Sep 30, 2014 | -43.92 Mn |
| Jun 30, 2014 | -44.39 Mn |
| Mar 31, 2014 | -268.81 Mn |
| Dec 31, 2013 | -32.36 Mn |
| Sep 30, 2013 | -29.69 Mn |
| Jun 30, 2013 | -18.17 Mn |
| Mar 31, 2013 | -9.01 Mn |
| Dec 31, 2012 | 43.64 Mn |
| Sep 30, 2012 | -19.50 Mn |
| Jun 30, 2012 | -12.96 Mn |
| Mar 31, 2012 | -11.37 Mn |
| Dec 31, 2011 | 43.18 Mn |
| Sep 30, 2011 | -13.24 Mn |
| Jun 30, 2011 | -13.82 Mn |
| Mar 31, 2011 | -16.29 Mn |
| Dec 31, 2010 | -6.93 Mn |
| Sep 30, 2010 | -9.63 Mn |
| Jun 30, 2010 | -14.63 Mn |
| Mar 31, 2010 | -12.32 Mn |
| Dec 31, 2009 | -7.79 Mn |
| Sep 30, 2009 | -9.21 Mn |
| Jun 30, 2009 | -22.70 Mn |